Cellis AG
Cellis AG is developing Macrophage Drug Conjugates (MDC). Our innovative approach is based on the groundbreaking discovery of the TRAIN mechanism unveiled by our team. Our technology works as a natural “Trojan Horse.” Our technology works as a natural “Trojan Horse.” By administering only a fraction of the drug dosage twice, we achieve a robust and durable activation of the immune system that leads to tumor regression and the development of anti-tumor resistance.
Date, time and room information
May 6, 15:45 - 16:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Revolutionizing Solid Tumors Treatment with Macrophage Drug Conjugates
Speaker information
| Name | Position | Institution |
|---|---|---|
| Magdalena Król | CSO | Cellis AG |
Further information for the sponsor website
